In short
This article explores the use of Dexpramipexole Dihydrochloride Monohydrate in clinical trials for treating eosinophilic asthma. Multiple phase III studies are examining the efficacy, safety, and tolerability of this drug in adolescents and adults with severe eosinophilic asthma. The trials aim to evaluate its effects on reducing asthma exacerbations, improving lung function, asthma control, and quality of life, as well as its impact on blood eosinophil levels.
At a glance
- Drug Name
- Dexpramipexole Dihydrochloride Monohydrate
- Condition Studied
- Severe Eosinophilic Asthma
- Trial Phase
- Phase III
- Administration
- Oral, film-coated tablets
- Dosages Studied
- 75 mg and 150 mg twice daily
- Primary Endpoints
- Reduction in severe asthma exacerbations, improvement in lung function (FEV1)
- Secondary Endpoints
- Asthma control (ACQ-6), quality of life (AQLQ+12), blood eosinophil levels
- Study Duration
- 24 to 52 weeks, with a long-term extension study
- Key Inclusion Criteria
- Age ≥12 years, diagnosed asthma for ≥12 months, on medium/high dose ICS, blood eosinophil count ≥0.30x10^9/L
- Key Exclusion Criteria
- Recent severe exacerbation, smoking history, certain cardiovascular conditions, renal or liver dysfunction
What is Dexpramipexole?
Dexpramipexole is an investigational drug being studied for the treatment of severe eosinophilic asthma. It is also known by its chemical name dexpramipexole dihydrochloride monohydrate and the code name KNS-760704. This medication is being developed by Areteia Therapeutics and is currently in Phase III clinical trials.
Mechanism of Action
While the exact mechanism of action is not fully described in the provided clinical trial information, dexpramipexole is believed to work by reducing the number of eosinophils in the blood. Eosinophils are a type of white blood cell that can contribute to inflammation in the airways of people with asthma. By lowering eosinophil levels, dexpramipexole may help reduce asthma symptoms and exacerbations in patients with eosinophilic asthma.
Clinical Trials
Several Phase III clinical trials are currently underway to evaluate the efficacy and safety of dexpramipexole in patients with severe eosinophilic asthma:
- EXHALE-2 and EXHALE-3: 52-week studies comparing dexpramipexole to placebo
- EXHALE-4: A 24-week study evaluating dexpramipexole's effects on lung function
- EXHALE-5: A long-term extension study assessing the safety and efficacy of dexpramipexole over an extended period
Efficacy
The primary goals of the clinical trials are to assess dexpramipexole's ability to:
- Reduce the rate of severe asthma exacerbations
- Improve lung function (measured by FEV1, or forced expiratory volume in 1 second)
- Enhance asthma control and quality of life
- Lower blood eosinophil counts
Results from these trials are not yet available, as the studies are ongoing.
Safety and Side Effects
The safety profile of dexpramipexole is still being evaluated in the ongoing clinical trials. Some potential areas of concern that are being monitored include:
- Effects on heart rhythm (QT interval prolongation)
- Liver function
- Kidney function
- Neutrophil counts (a type of white blood cell)
Patients with a history of certain medical conditions, such as heart problems, liver disease, or kidney disease, may be excluded from the trials due to potential safety concerns.
Administration
Dexpramipexole is being studied as an oral medication in the form of film-coated tablets. In the clinical trials, it is being tested at doses of 75 mg and 150 mg, taken twice daily. The medication is intended to be taken in addition to patients' standard asthma treatments, such as inhaled corticosteroids and other controller medications.
Patient Population
Dexpramipexole is being studied in patients with severe eosinophilic asthma. Key characteristics of the target patient population include:
- Age 12 years and older (18 and older in some countries)
- Diagnosis of asthma for at least 12 months
- Elevated blood eosinophil levels (≥0.30 x 10^9/L)
- Inadequate asthma control despite treatment with medium to high-dose inhaled corticosteroids and additional controller medications
- History of asthma exacerbations requiring systemic corticosteroids
Future Research
As the Phase III clinical trials for dexpramipexole are ongoing, future research will focus on analyzing the results of these studies to determine the drug's efficacy and safety profile. If the results are positive, the next steps may include:
- Submitting applications for regulatory approval
- Conducting additional studies to evaluate long-term safety and efficacy
- Investigating the drug's potential in other eosinophilic conditions
It's important to note that dexpramipexole is still an investigational drug and is not currently approved for use outside of clinical trials. Patients with severe eosinophilic asthma should consult with their healthcare providers about currently available treatment options and the possibility of participating in clinical trials.